Anaphylaxis Clinical Tool Has Launched
Food Allergy Research & Education released a digital tool to improve epinephrine administration protocols.
Updated on Oct. 6, 2026 in Allergies
Live Poll
Do you trust clinical software tools to assist doctors in making high-stakes medical treatment decisions?
Food Allergy Research & Education has introduced Anatool, a new digital clinical support tool designed to guide medical professionals in the identification and treatment of anaphylaxis. The platform utilizes embedded algorithms and current consensus criteria to provide clinicians with weight-based epinephrine dosing instructions.
Why it matters
Clinicians have historically struggled with the underuse of epinephrine in community settings, often because traditional paper-based pathways are oversimplified or ignored. This digital tool aims to standardize emergency responses by providing immediate, step-by-step guidance for severe allergic reactions.
The tool uses criteria from the 2024 anaphylaxis consensus report to calculate patient-specific doses. Research indicates that only 21% of children and 7% of adults receive epinephrine before arriving at a hospital, highlighting the need for better clinical support.
The players
Food Allergy Research & Education
This non-profit organization is dedicated to research, advocacy, and education regarding food allergies and anaphylaxis.
Altrix Medical
This company provides specialized medical technology and software development support for healthcare applications.
Cincinnati Children's Hospital Medical Center
This pediatric academic medical center served as the workplace for a lead developer involved in the creation of Anatool.
The details
Developed with assistance from Altrix Medical, the Anatool platform requires users to verify their status as healthcare professionals before accessing its features. Users can input allergen exposure details and symptom responses, allowing the software to generate clinical recommendations and track reassessment timing.
Timeline
2006: NIAID/FAAN anaphylaxis criteria were published.
2024: International anaphylaxis consensus recommendations were published.
October 6, 2026: The article detailing the Anatool release was published.
The Big Picture
The development of the Anatool platform follows the clinical standards established in the 2024 anaphylaxis consensus report. This digital transition aims to bridge the gap between static, historical guidance and dynamic, real-time medical decision support.
While this tool is currently restricted to verified healthcare professionals, the upcoming patient-facing app may eventually change how caregivers manage severe allergies at home. Improved clinical accuracy in emergency settings is expected to reduce the time to treatment for patients suffering from anaphylaxis.
The takeaway
Standardizing clinical responses to anaphylaxis through digital tools can significantly decrease the underuse of life-saving epinephrine. Healthcare providers should review the updated 2024 consensus criteria to ensure their practices align with the latest emergency medical recommendations.
Further reading
For additional information on identifying and managing severe reactions, visit the Allergies section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust clinical software tools to assist doctors in making high-stakes medical treatment decisions?
